Bloomberg Law
Free Newsletter Sign Up
Bloomberg Law
Advanced Search Go
Free Newsletter Sign Up

Alvotech Resolves Patent, Trade Secret Disputes With AbbVie

March 8, 2022, 10:13 PM

Alvotech secures U.S. rights for its proposed Humira biosimilar.

  • Expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
  • All ongoing U.S. disputes between AbbVie and Alvotech have been resolved, including the ITC action brought forth in December
  • NOTE: Dec. 7, Alvotech Going Public Through Oaktree SPAC Merger


  • AbbVie Inc. rose 0.0% in postmarket trading to $147.19 as of 5:10 p.m. New York time
    • The average 12-month price target of $152.55 is 3.6% above the current price
    • 18 buys, 7 holds, 1 sells

To view the source of this information, click here ...